Brief: Bioporto Adjusts FY 2026 Guidance Following Antibody Business Divestment
08/04/2026 14:22
April 8 (Reuters) - Bioporto A/S BIOPOR.CO: BIOPORTO SUCCESSFULLY COMPLETES DIVESTMENT OF ITS ANTIBODY BUSINESS TO JANEL LIFE SCIENCES, LLC ADJUSTS FY 2026 GUIDANCE FOLLOWING ANTIBODY BUSINESS DIVESTMENT SEES FY 2026 REVENUE DKK 38-48 MILLION, ADJUSTED EBITDA LOSS DKK 58-68 MILLION TARGETS FY 2028 REVENUE DKK 135-185 MILLION, CASH FLOW POSITIVE IN H1 2028 SEES ACCOUNTING GAIN OF DKK 54 MILLION ON EBITDA AND NET PROFITS FROM DEAL UPDATED GUIDANCE: 2026 ADJUSTED. EBITDA LOSS OF DKK 58-68 MILLION Source text: ID:nGNE2cJ34C Further company coverage: BIOPOR.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))